From Tubes to Tumor Prevention: Systematic Review and Meta-analayses on Salpingectomy Uptake and Impact
Authors
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Background: Salpingectomy, once used for sterilization or ectopic pregnancy, has been explored more and more as a preventive strategy for ovarian cancer. Its oncologic value, surgical acceptability, rising global application have been lately reported in evidence, but in-depth knowledge of its clinical application is rare. Aim and Objective: To what degree has salpingectomy been taken up as a prevention for ovarian cancer in clinical practice worldwide, and what is the new evidence for its oncologic benefit, safety, and utilization from 2020 to 2025? Material and Methods: Systematic review and meta-analysis were conducted by searching the electronic databases of PubMed, Embase and Scopus for the published studies between 2020 and 2025. Studies included reported on salpingectomy for ovarian cancer prevention, with uptake, safety, or oncologic outcomes data. Meta-analysis was conducted on extractable incidence data using a random-effects model. A total of 10 studies were finally selected from 425 articles of which 3 articles were considered for meta analyses with a total of subject of 504390. Results: Salpingectomy revealed uniformly low rate of ovarian cancer (range: 0.00069 to 0.00094) in included studies. The pooled effect estimate was 0.00 [0.00, 0.00], which was statistically significant (t = 13.52, p = 0.005), showing a consistently low rate of ovarian cancer after salpingectomy. Barriers were training shortage, complexity of consent, and resistance at the system level. A single randomized controlled trial demonstrated similar surgical safety. Conclusion: Salpingectomy is now a promising and increasingly popular preventive intervention for ovarian cancer. With the accrual of mounting evidence supporting its safety and effectiveness, the way forward should be in the direction of international harmonization of guidelines, training, and interfacing with digital surgical platforms.
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2025 Rajathi Sampath Kumar , Rajeshwari Balu, Jothikala C, Swathi N, Jamila Hameed
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons License All articles published in Annals of Medicine and Medical Sciences are licensed under a Creative Commons Attribution 4.0 International License.
Rajathi Sampath Kumar , Department of Obstetrics and Gynaecology, District Headquarters Hospital, Pollachi, Tamil Nadu, India.
Department of Obstetrics and Gynaecology, District Headquarters Hospital, Pollachi, Tamil Nadu, India.
Rajeshwari Balu, Department of Obstetrics and Gynaecology, District Headquarters Hospital, Pollachi, Tamil Nadu, India.
Department of Obstetrics and Gynaecology, District Headquarters Hospital, Pollachi, Tamil Nadu, India.
Jothikala C, Department of Obstetrics and Gynaecology, District Headquarters Hospital, Pollachi, Tamil Nadu, India.
Department of Obstetrics and Gynaecology, District Headquarters Hospital, Pollachi, Tamil Nadu, India.
Swathi N, Statistician, Department of Medical Research, Karuna Medical College, Vilayodi, Chittur, Palakkad, Kerala, India.
Statistician, Department of Medical Research, Karuna Medical College, Vilayodi, Chittur, Palakkad, Kerala, India.
Jamila Hameed, Department of Obstetrics and Gynaecology, Karuna Medical College, Vilayodi, Chittur, Palakkad, Kerala, India.
Emiratus Professor, Research Mentor, Department of Obstetrics and Gynaecology, Karuna Medical College, Vilayodi, Chittur, Palakkad, Kerala, India.
[1] Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? American journal of obstetrics and gynecology. 2011 Jan 1;204(1):19-e1.
[2] Balsarkar G. Opportunistic salpingectomy as an ovarian cancer primary prevention strategy. The Journal of Obstetrics and Gynecology of India. 2017 Aug; 67:243-6.
[3] Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Frontiers in oncology. 2014 Feb 10;4:21.
[4] Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proceedings of the National Academy of Sciences. 2014 Sep 30;111(39):14205-10.
[5] Gasparri ML, Taghavi K, Fiacco E, Zuber V, Di Micco R, Gazzetta G, Valentini A, Mueller MD, Papadia A, Gentilini OD. Risk-reducing bilateral salpingo-oophorectomy for BRCA mutation carriers and hormonal replacement therapy: if it should rain, better a drizzle than a storm. Medicina. 2019 Jul 29;55(8):415.
[6] Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation. Gynecologic oncology. 2019 Jan 1;152(1):145-50.
[7] Wilczyński J, Paradowska E, Wilczyński M. High-grade serous ovarian cancer-A risk factor puzzle and screening fugitive. Biomedicines. 2024 Jan 19;12(1):229.
[8] Boerner T, Roche KL. Salpingectomy for the risk reduction of ovarian cancer: is it time for a salpingectomy-alone approach?. Journal of minimally invasive gynecology. 2021 Mar 1;28(3):403-8.
[9] Conduit C, Milne RL, Friedlander ML, Phillips KA. Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: assessing the evidence. Cancer Prevention Research. 2021 Nov 1;14(11):983-94.
[10] Gelderblom ME, Van Lieshout LA, Piek JM, De Hullu JA, Hermens RP. Patients’ and professionals’ perspectives on implementation of opportunistic salpingectomy: a mixed-method study. BMC Health Services Research. 2021 Dec; 21:1-4.
[11] Pölcher M, Hauptmann S, Fotopoulou C, et al. Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar. Geburtshilfe Frauenheilkd. 2015;75(4):339-341. doi:10.1055/s-0035-1545958
[12] Hanley GE, Niu J, Han J, Fung S, Bryant H, Kwon JS, Huntsman DG, Finlayson SJ, McAlpine JN, Miller D, Earle CC. Opportunistic salpingectomy between 2011 and 2016: a descriptive analysis. Canadian Medical Association Open Access Journal. 2022 Apr 1;10(2):E466-75.
[13] Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH. Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prevention Research. 2015 May 1;8(5):342-8.
[14] Gelderblom ME, Jaspers V, Akkermans RP, Slangen B, Oei AL, van Ginkel AA, Ngo H, IntHout J, Hermens RP, de Hullu JA, Piek JM. First step in implementation of opportunistic salpingectomy for prevention of ovarian cancer: Current care and its determinants. Acta obstetricia et gynecologica Scandinavica. 2023 Mar;102(3):257-69.
[15] Samimi G, Trabert B, Geczik AM, Duggan MA, Sherman ME. Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-Fim protocol. JNCI Cancer Spectrum. 2018 Oct;2(4): pky061.
[16] Runnebaum IB, Kather A, Vorwergk J, Cruz JJ, Mothes AR, Beteta CR, Boer J, Keller M, Pölcher M, Mustea A, Sehouli J. Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany. Journal of Cancer Research and Clinical Oncology. 2023 Aug;149(10):6953-66.
[17] Giannakeas V, Murji A, Lipscombe LL, Narod SA, Kotsopoulos J. Salpingectomy and the risk of ovarian cancer in Ontario. JAMA Network Open. 2023 Aug 1;6(8):e2327198.
[18] Bacha OM, Gregoire J, Grondin K, Edelweiss MI, Laframboise R, Simard J, Plante M. Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. International Journal of Gynecological Cancer. 2012 Jul 1;22(6):974-8.
[19] Gootzen TA, Steenbeek MP, van Bommel MH, IntHout J, Kets CM, Hermens RP, de Hullu JA. Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy. Familial Cancer. 2024 Nov;23(4):437-45.
[20] Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AH, Prins JB, Bulten J, Teerenstra S, Adang EM, Piek JM, van Doorn HC, van Beurden M. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC cancer. 2015 Dec;15:1-9.
[21] Yen JC, Wu TI, Stone R, Wang TL, Visvanathan K, Chen LY, Hsu MH, Shih IM. Salpingectomy for ectopic pregnancy reduces ovarian cancer risk-a nationwide study. JNCI Cancer Spectrum. 2024 Jun 1;8(3): pkae027.
[22] Long Roche KC, Abu‐Rustum NR, Nourmoussavi M, Zivanovic O. Risk‐reducing salpingectomy: Let us be opportunistic. Cancer. 2017 May 15;123(10):1714-20.
[23] Strandell A, Magarakis L, Sundfeldt K, Pålsson M, Liv P, Idahl A. Salpingectomy versus tubal occlusion in laparoscopic sterilisation (SALSTER): a national register-based randomised non-inferiority trial. The Lancet Regional Health–Europe. 2024 Oct 1;45.
[24] Magarakis L, Idahl A, Sundfeldt K, Liv P, Pålsson M, Strandell A. SALpingectomy for STERilisation (SALSTER): study protocol for a Swedish multicentre register-based randomised controlled trial. BMJ open. 2023 Sep 1;13(9):e071246.
[25] Lukey A, Howard A, Mei AJ, Law MR, Huntsman D, Pearce CL, Meza R, Hanley GE. Risk-reducing salpingectomy: considerations from an OBGYN perspective. BMC cancer. 2025 Dec;25(1):1-8.
[26] Kamran MW, Vaughan D, Crosby D, Wahab NA, Saadeh FA, Gleeson N. Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC). European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013 Sep 1;170(1):251-4.